RxDoctor Payments Data

Manisha Bhutani, MD

Internal Medicine · Fishkill, NYNPI 1679662464

Payments from drug & device makers

$391,328in general payments, 2019–2025

Across 453 payments — averaging $863.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$378K
  • Tosoh Bioscience, Inc.$4K
  • Novo Nordisk$2K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$696
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$11,53174%
  • Education$250%
  • Gifts$4,00626%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$391,328 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$117,445
Medicare patients
332
Services billed
2,682

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide101$200,712
EliquisApixaban49$51,267
FarxigaDapagliflozin Propanediol31$44,810
JardianceEmpagliflozin23$35,843
JanuviaSitagliptin Phosphate20$32,324
XareltoRivaroxaban25$31,624
JanumetSitagliptin Phos/Metformin Hcl22$25,612
TrulicityDulaglutide18$24,740
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$17,578
Breo ElliptaFluticasone/Vilanterol16$6,659
SynthroidLevothyroxine Sodium87$6,381
Atorvastatin Calcium437$5,828
Levothyroxine Sodium341$4,965
Albuterol Sulfate HfaAlbuterol Sulfate83$3,572
Duloxetine Hcl56$2,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog Mix 70-30$1,986$203,485114 claims
MerckJanuvia, Janumet$53$57,93642 claims
PfizerEliquis, Paxlovid$289$52,69661 claims
AstraZenecaFarxiga$378,003$44,81031 claims
Boehringer IngelheimJardiance$1,046$35,84323 claims
Johnson & JohnsonXarelto$112$31,62425 claims
Lilly USA, LLCTrulicity$696$24,74018 claims
GSKTrelegy Ellipta, Breo Ellipta$1,248$24,23743 claims
AbbVieSynthroid$671$6,38187 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$95$4,965341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Fishkill

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →